ROIV · Roivant Sciences Ltd
United States · RS rating 88 · As of 2026-11-03
| Price | 36.04 USD |
|---|---|
| 1-day change | +0.4% |
| RS rating (overall / 1M / 3M / 12M) | 88 / 60 / 75 / 92 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 46 / 51 / 35 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -124.4% |
| Sales growth Q/Q | +27.2% |
| Distance from 52-week high | +13.8% |
| Market cap (USD) | $20.1B |